A cellular protein whose normal function appears to suppress bone formation may be a potential new target for treating osteoporosis, suggests a collaborative study led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
The Office of Academic Integration (OVPAI) has awarded $750,000 in seed grants to 10 studies ranging from refugee health and legal rights, to a vaccine treating fentanyl addiction and overdose, to pancreatic cancer and antibiotic tolerance.
Common symptoms of the genetic disorder neurofibromatosis type 1 (NF1), including skeletal fragility and the loss of bone mass, may be treatable with an existing anti-cancer drug, according to a study from researchers at Weill Cornell Medicine.
Dr. Matthew Greenblatt, an assistant professor of pathology and laboratory medicine at Weill Cornell Medicine, has been awarded the 2019 Pershing Square Sohn Prize for Young Investigators in Cancer Research to support his work studying tumor growth in bone.
Eight Weill Cornell Medicine faculty members have been selected for the fifth round of the Daedalus Fund for Innovation awards, a pioneering institutional program that helps advance promising applied and translational research projects and emerging technologies that have commercial potential.
A type of stem cell newly discovered by Weill Cornell Medicine and NewYork-Presbyterian investigators is responsible for growing and healing the hard, outer surface of bone.
A molecule promoting blood vessel growth in bone can create an environment suitable for bone-building formation, representing a potential target for new drugs to treat osteoporosis and fractures, according to new research by Weill Cornell Medicine scientists.
